UPDATE 1-Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports

-0.43%

-1.86%

-1.94%

-1.78%

-2.61%

Becton, Dickinson and Company BDX	167.22	-0.43%
Thermo Fisher Scientific Inc. TMO	403.13	-1.86%
Waters Corporation WAT	344.06	-1.94%
Revvity, Inc. Common Stock RVTY	91.25	-1.78%
Danaher Corporation DHR	189.73	-2.61%

Rewrites headline, adds details and background in paragraphs 2-6, stock movement in paragraph 3

April 1 (Reuters) - U.S. medical device maker Becton Dickinson BDX.N is in talks with Thermo Fisher TMO.N and Danaher DHR.N for a potential sale of its life sciences unit, the Financial Times reported on Tuesday.

Becton Dickinson had in February announced its plan to separate the unit, which consists of biosciences and diagnostic solutions, after the Financial Times reported that activist Starboard Value had taken a stake in the company and was pushing for the divestiture.

Its shares have fallen about 7.5% since then.

The unit could be worth as much as $21.5 billion, the FT reported, citing analysts at Bank of America.

Becton Dickinson is also exploring a so-called Reverse Morris trust tax-free deal with smaller diagnostics players such as Waters Corp WAT.N, Qiagen QIA.DE and Revvity RVTY.N, the report said, citing sources familiar with the matter.

Becton's biosciences and diagnostic solutions unit makes diagnostic products such as those used to detect infectious diseases and cancers.

Becton Dickinson, Thermo Fisher Scientific, Danaher, Waters Corp, Qiagen and Revvity did not immediately respond to a Reuters request for comment.

(Reporting by Surbhi Misra and Shubham Kalia in Bengaluru; Editing by Varun H K)

((Surbhi.Misra@thomsonreuters.com | X: https://twitter.com/SurbhiMisra_ |;))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.